Hsp90β inhibitors prevent GLT-1 degradation but have no beneficial efficacy on absence epilepsy.
In: Journal of Asian Natural Products Research, Jg. 21 (2019-09-01), Heft 9, S. 905-915
academicJournal
Zugriff:
The loss of glutamate transporter-1 (GLT-1) is associated with temporal lobe epilepsy (TLE). A recent study reported that Hsp90β interacted with GLT-1 and recruited it to 20S proteasome for degradation. Therefore, inhibiting Hsp90β may be a new strategy for treating epilepsy. So far, no studies have shown whether the inhibition of Hsp90β had therapeutic effects on absence epilepsy. Using a model of absence epilepsy, we demonstrated that 17-allylamino-17-demethoxygeldanamycin (17AAG) and Ganetespib (STA9090) had no therapeutic effect. Although this is a negative result, it also has a meaningful exploration value for whether Hsp90 inhibitors have therapeutic effects on other epilepsy types. [ABSTRACT FROM AUTHOR]
Copyright of Journal of Asian Natural Products Research is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Hsp90β inhibitors prevent GLT-1 degradation but have no beneficial efficacy on absence epilepsy.
|
---|---|
Autor/in / Beteiligte Person: | Peng, Yu-Chen ; Wang, Shan ; Zhang, Yong ; Huang, Long-Jian ; Wang, Xiao-Liang ; Peng, Ying |
Zeitschrift: | Journal of Asian Natural Products Research, Jg. 21 (2019-09-01), Heft 9, S. 905-915 |
Veröffentlichung: | 2019 |
Medientyp: | academicJournal |
ISSN: | 1028-6020 (print) |
DOI: | 10.1080/10286020.2018.1530989 |
Schlagwort: |
|
Sonstiges: |
|